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Development and progression of nephropathy in type 2 dia- The burden of diabetic renal disease, recognized since
betes: The United Kingdom Prospective Diabetes Study (UKPDS 64). the second century a.d. [1], is formidable. Diabetes is
Background. The progression of nephropathy from diagno- estimated to increase the risk of end-stage renal disease
sis of type 2 diabetes has not been well described from a single (ESRD) approximately 12-fold [2]. In comparison to thepopulation. This study sought to describe the development and
general population, a disproportionately large percent-progression through the stages of microalbuminuria, macroal-
age of patients with ESRD have diabetes; estimates varybuminuria, persistently elevated plasma creatinine or renal re-
placement therapy (RRT), and death. from approximately 25% in the UK and Canada to over
Methods. Using observed and modeled data from 5097 sub- 40% in the US [3–5]. Diabetic nephropathy is the main
jects in the UK Prospective Diabetes Study, we measured the reason for renal replacement therapy in the UK [3].
annual probability of transition from stage to stage (incidence), Type 2 diabetes accounts for over 90% of diabetes,
prevalence, cumulative incidence, ten-year survival, median
and yet the natural history of nephropathy from prospec-duration per stage, and risk of death from all-causes or cardio-
tive data is less well described for type 2 than for type 1vascular disease.
[6]. Many studies of patients with type 2 diabetes haveResults. From diagnosis of diabetes, progression to micro-
albuminuria occurred at 2.0% per year, from microalbuminuria been limited by their inclusion of either early [7–9] or
to macroalbuminuria at 2.8% per year, and from macroalbu- late [2] nephropathy. Comprehensive studies tend to be
minuria to elevated plasma creatinine (175 mol/L) or renal limited to one ethnic group [10–15], or have fewer than
replacement therapy at 2.3% per year. Ten years following 200 subjects [7, 8, 16]. Hence, the estimates for the ratesdiagnosis of diabetes, the prevalence of microalbuminuria was
of progression through the stages of diabetic nephropa-24.9%, of macroalbuminuria was 5.3%, and of elevated plasma
thy are rare or imprecise. Also, data estimating survivalcreatinine or RRT was 0.8%. Patients with elevated plasma
are sparse, including the average duration spent in eachcreatinine or RRT had an annual death rate of 19.2% (95%
confidence interval, CI, 14.0 to 24.4%). There was a trend for stage of nephropathy, which is information that would
increasing risk of cardiovascular death with increasing ne- expand our understanding of the development, progres-
phropathy (P  0.0001), with an annual rate of 0.7% for sub- sion, and burden of nephropathy in type 2 diabetes.
jects in the stage of no nephropathy, 2.0% for those with micro- To describe and clarify the natural history of nephrop-albuminuria, 3.5% for those with macroalbuminuria, and 12.1%
athy in treated type 2 diabetes, this article estimates fromwith elevated plasma creatinine or RRT. Individuals with macro-
diagnosis of diabetes the risk of developing persistentalbuminuria were more likely to die in any year than to develop
renal failure. microalbuminuria and progressing to persistent macro-
Conclusions. The proportion of patients with type 2 diabetes albuminuria, persistently elevated plasma creatinine or
who develop microalbuminuria is substantial with one quarter renal replacement therapy, and death. Using data from
affected by 10 years from diagnosis. Relatively fewer patients over 5000 patients in the United Kingdom Prospective
develop macroalbuminuria, but in those who do, the death rate
Diabetes Study (UKPDS), we report the progression fromexceeds the rate of progression to worse nephropathy.
stage to stage, and the likelihood of death from cardio-
vascular disease. We report the cumulative incidence and
Key words: type 2 diabetes, microalbuminuria, macroalbuminuria, in- prevalence of nephropathy, and use modeling techniques
sulin, plasma creatinine, nephropathy, end-stage renal disease. to extrapolate the course of renal disease beyond the
period of observation in order to estimate the proportionReceived for publication March 20, 2002
and in revised form July 17, 2002 of patients who survive ten years following onset of a
Accepted for publication August 12, 2002 given stage of nephropathy, and to estimate the median
time spent in each stage of nephropathy. 2003 by the International Society of Nephrology
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METHODS was 300 mg/L at two consecutive annual visits and
their plasma creatinine was175 mol/L, or if a urinaryStudy population
albumin value 300 mg/L was followed in the next yearThe UKPDS is a randomized, non-blinded clinical trial
by elevated plasma creatinine, renal replacement ther-that investigated the effects of intensive policies for the
apy, or death from renal or cardiovascular causes. Atcontrol of blood glucose and blood pressure on the com-
diagnosis of diabetes, patients were considered to haveplications of type 2 diabetes. The study enrolled 5102
macroalbuminuria if their urine albumin was300 mg/L(67%) with newly diagnosed type 2 diabetes of the 7616
at their first two measurements.referred. Exclusions pertinent to nephropathy include
Elevated plasma creatinine or renal replacement thera-plasma creatinine concentration175mol/L, a history of
py. Patients were designated as being in the stage ofmyocardial infarction in the previous year, current heart
elevated plasma creatinine or renal replacement therapyfailure, and malignant hypertension. Patients were aged
if their plasma creatinine was 175 mol/L on two con-25 to 65 years, were white, South Asian, Afro-Caribbean
secutive visits, or if a creatinine 175 mol/L was fol-or other ethnicities, and were recruited to the UKPDS if
lowed the next year by renal dialysis, renal transplant,their fasting plasma glucose (FPG) was 6 mmol/L
or death.(108 mg/dL) on two occasions. Patients were placed on
a three-month low-fat, high-carbohydrate diet. The trial Death
ran from 1977 to 1997, and the design, therapies, and
Cause of death was adjudicated by two physicians asresults have been published previously [17–20]. Of the
previously described [25]. Cardiovascular death included5102 enrolled in the UKPDS, 5097 with urine albumin
deaths from stroke, myocardial infarction, sudden deathmeasurements available were included in these analyses.
and peripheral vascular disease. Death from uremia was
defined as a plasma creatinine 250 mol/L in subjectsBiochemical measurements
in whom there was no other recorded cause of death.Plasma creatinine was measured annually by labora-
tories local to each clinical center. Other biochemical Statistical methods
measurements were made in the central laboratory as
Individuals were followed from diagnosis of diabetesdescribed [17, 21]. Urinary albumin concentration was
to the onset of a given stage of nephropathy or to censor-measured from annual morning spot urine samples from
ing. The data were annualized and years-at-risk calculated.1988 to the end of the study by an immunoturbidimetric
Annual transition probabilities were used to estimatemethod in samples containing thiomersal following stor-
the incidence rates and 95% confidence intervals (CI),age at 4C [21, 22] and before 1988 by radioimmunoassay
and were calculated from life table analysis. The analysesin samples frozen at 20C [23]. The UKPDS defined
describe the experience of the cohort as a whole and aremicroalbuminuria as a urine albumin concentration of
unadjusted for risk factors for nephropathy. Cumulative50 mg/L based on the 96th percentile of a non-diabetic
incidence was calculated by life table methods for thereference population [24] and because storage at 20C
development of each stage of nephropathy. The preva-reduced albumin levels in the lower range [17].
lence was calculated as the proportion of subjects with a
Stages of nephropathy given stage of nephropathy or worse at 5, 10, and 15 years.
To test the hypothesis that the risk of cardiovascularNo nephropathy. Patients were designated as having
death increases with worsening nephropathy, Mantel’sno nephropathy if they did not have microalbuminuria,
generalization of the Mantel-Haenszel test was used [26].macroalbuminuria, a persistently elevated plasma creati-
We used a multi-state Markov model [27] to estimatenine or renal replacement therapy as defined below.
prevalence beyond the period of observation, the pro-Microalbuminuria. Patients were designated as being
portion of patients who remain alive ten years from thein the stage of microalbuminuria if their urine albumin
onset of a given stage of nephropathy, and the medianwas in the range of 50 to 299 mg/L on two consecutive an-
time spent in each stage. The model and simulation rannual visits and their plasma creatinine was175 mol/L
in units of one year and assumed that a patient remainedor a urinary albumin value of 50 to 299 mg/L was fol-
in the same stage of nephropathy or worsened.lowed in the next year by macroalbuminuria, elevated
To examine the sensitivity of the results to the inclusionplasma creatinine, renal replacement therapy, or death
of patients with microalbuminuria, macroalbuminuria orfrom renal or cardiovascular causes. At diagnosis of dia-
elevated plasma creatinine at diagnosis of diabetes, inci-betes, patients were considered to have microalbumin-
dence rates were recalculated for the 4993 patients withuria if their urine albumin was in the range of 50 to
plasma creatinine120mol/L, and for the 4639 individ-299 mg/L at their first two measurements.
uals who, in addition, were in the no nephropathy stageMacroalbuminuria. Patients were designated as being
in the stage of macroalbuminuria if their urine albumin at diagnosis of diabetes.
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Table 1. Patient characteristics at diagnosis of diabetes Annual death rates
Age years 52.1 (8.8) Annual death rates increased with increasing nephrop-
Sex male 59% athy (Fig. 1). The annual death rate from the no nephrop-Ethnicity White/Indian Asian/Afro-
athy stage was 1.4%, from microalbuminuria was 3.0%,Caribbean/other 81.9%/9.7%/7.6%/0.8%
Body mass index kg/m2 27.5 (5.4) and from macroalbuminuria was 4.6%. Patients with ele-
Microalbuminuria 6.5% vated plasma creatinine or renal replacement therapyMacroalbuminuria 0.7%
had an annual death rate of 19.2%, including 4.0% (1.4Plasma creatinine lmol/L 82.5 (17.5)
HbA1c % 7.2 (1.8)a to 6.6%) per year who died from uremia. Patients with
Systolic blood pressure mm Hg 135 (19.5) elevated plasma creatinine, but without RRT, had anDiastolic blood pressure mm Hg 83 (10.2)
annual death rate of 18.9% (13.3 to 24.6%). For patientsAntihypertensive treatment at
diagnosis of diabetes 18% with macroalbuminuria, the annual death rate of 4.6%
Cholesterol mmol/L 5.4 (1.1)
(3.5 to 5.7%) exceeded the rate of progression to worseTriglycerideb mmol/L 1.5 (0.9–2.7)
Smokers never, former, current 35%/34%/31% nephropathy (2.3%; 1.5 to 3.0%). Relative to patients
in the stage of no nephropathy, those with microalbumin-Data are given as mean and standard deviation; N  5097. Values for lipids,
hemoglobin A1c (HbA1c), blood pressure and body mass index were measured uria, macroalbuminuria, or an elevated plasma creatinine
3 months following diagnosis of diabetes after a low fat and low calorie (if
or renal replacement therapy had a 2.2-fold, 3.4-fold,overweight) diet.
a Numbers vary by variable and 13.9-fold increased risk of death, respectively.b Geometric mean (1 SD range)
The most common cause of death at all stages of ne-
phropathy was cardiovascular disease with a trend for
increasing risk of cardiovascular death with increasing
RESULTS nephropathy (P  0.0001). The annual death rate due
The characteristics of the study population are pre- to cardiovascular disease was 0.7% for subjects in the
sented in Table 1. Of the 5097 individuals, 4727 (92.7%) no nephropathy stage, 2.0% for those with microalbu-
were in the no nephropathy stage, 333 (6.5%) had micro- minuria, and 3.5% for those with macroalbuminuria and
albuminuria, and 37 (0.7%) had microalbuminuria. Dur- 12.1% for those with elevated plasma creatinine or renal
ing the median follow-up of 10.4 years, a further 867 replacement therapy. Similarly, the proportion of all deaths
developed microalbuminuria, 264 macroalbuminuria, 71 due to cardiovascular disease increased with each stage of
elevated plasma creatinine 175 mol/L, and 14 re- increasing albuminuria being 51% of deaths in no nephrop-
quired renal replacement therapy (RRT). Seventeen athy stage, 66% of deaths in those with microalbuminuria,
deaths were attributed to renal disease during the study. and 75% of deaths in those with macroalbuminuria.
There were 42,929 person-years at-risk of follow-up from
the stage of no nephropathy, 7132 from microalbumin- Prevalence
uria, 1464 from macroalbuminuria, and 224 from ele- The prevalence of different stages of nephropathy is
vated plasma creatinine or renal replacement therapy. shown in Table 3 for increasing duration of diabetes. At
diagnosis of diabetes 7.3% of patients had microalbumin-Annual nephropathy transition rates from stage to stage
uria or worse rising to 17.3% after 5 years, 24.9% after 10The annual rates of transition from stage to stage of
years and 28.0% after 15 years. For comparison, modelednephropathy and to death are shown in Figure 1. Patients
values for prevalence are presented. Projections basedprogressed from no nephropathy to microalbuminuria
on the model show that 34.3% of patients with type 2at a rate of 2.0% per year, then to macroalbuminuria at
diabetes are likely to have persistent microalbuminuria2.8% per year, and then to elevated plasma creatinine
or worse by 20 years and 38.3% by 25 years.or renal replacement therapy at 2.3% per year. Individu-
Of 2799 patients in the study at 10 years, 696 hadals had a lower probability (1% per year) of prog-
microalbuminuria or worse nephropathy. Of these, 507ressing directly from no nephropathy to macroalbumin-
had developed it since the onset of diabetes, while 164uria, or directly from microalbuminuria to elevated plasma
had had microalbuminuria and 25 macroalbuminuria atcreatinine or renal replacement therapy.
diagnosis of diabetes. Three of the 696 individuals re-Table 2 shows the annual probability of not deteriorat-
quired renal replacement therapy within 10 years and aing in a given year to a more advanced stage of nephropa-
further 19 had persistent elevated plasma creatininethy or to death. The annual probability of not progressing
175 mol/L.was93% for all stages except for elevated plasma creat-
inine or renal replacement therapy, which was 80.8%.
Survival at ten yearsSensitivity analyses excluding patients who had micro-
The proportion of patients alive at ten years followingalbuminuria, macroalbuminuria, or a plasma creatinine
onset of a given stage of nephropathy is shown in Table 4.120mol/L at diagnosis of diabetes made no significant
difference to the rates of progression. Of patients with no nephropathy at diagnosis of diabetes,
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Fig. 1. Annual transition rates with 95% confidence intervals through the stages of nephropathy and to death from any cause.
Table 2. Annual probability (and 95% CI) of not progressing to a microalbuminuria or worse nephropathy. We also esti-
more advanced stage of nephropathy or to death
mate that half of patients who develop microalbuminuria
Annual probability of do so within 19 years from diagnosis of diabetes. From
Stage remaining in stage 95% CI any stage of nephropathy, the rate of deterioration to
No nephropathy 96.4% 96.2%–96.6% the next stage is 2 to 3% per year. Subjects with micro-
Microalbuminuria 93.8% 93.3%–94.4%
albuminuria are not necessarily destined for worse renalMacroalbuminuria 93.1% 91.8%–94.4%
Elevated plasma creatinine function, and subjects with macroalbuminuria and ele-
or renal replacement therapy 80.8% 75.6%–86% vated plasma creatinine have a greater probability of dying
than of requiring renal replacement therapy in any year.
With advancing nephropathy, the mortality rate increases.
87.1% were alive after ten years. Decreasing proportions In comparison with this study, other studies show that
of patients were alive at 10 years for worsening stages a greater proportion of patients developed microalbu-
of nephropathy falling to 8.5% for those with elevated minuria over a shorter time period [7–9, 28]. Among
plasma creatinine or renal replacement therapy. By com- normoalbuminuric patients in Denmark, 20% developed
parison, the modeled value was 11.9% (CI, 6.1 to 22.1%). microalbuminuria during a follow-up of 5.8 years, while
in Israel 35% developed it during a follow-up of eightMedian duration of each stage of nephropathy
years [7, 9]. Our model suggests that 11.1% of patients
Model-derived estimates of the time spent in each stage would develop microalbuminuria or worse in six years
of nephropathy were a median of 18.9 years [interquar- and 13.7% within eight years (cumulative incidence).
tile range (IQR), 7.8 years, 37.8 years] for individuals
The lower rates may be due to differences in ethnicity,
with no nephropathy at diagnosis of diabetes, 10.9 years
health care, comorbidity, risk factors for nephropathy,
(IQR, 4.5, 21.8) for those with microalbuminuria, 9.7 years
duration of diabetes (since UKPDS subjects were newly(IQR, 4.0, 19.4) for those with macroalbuminuria, and
diagnosed), the use of annualized data, the use of dif-2.5 years (IQR, 1.0, 5.0) for those with elevated plasma
fering definitions such as a urinary albumin 50 mg/L orcreatinine before requiring renal replacement treatment.
successive annual tests to define microalbuminuria. It isPatients on renal replacement therapy had a median
difficult to assess the comparability of the UKPDS popula-survival (life expectancy) of 3.0 years (IQR, 1.3, 6.0).
tion to other diabetic populations in the UK, in part
because some 3 in 10 patients with diabetes lack hemo-
DISCUSSION globin A1c (HbA1c) data within the past year [29]. Com-
pared to a national US sample, the UKPDS populationThis article describes the natural history of renal dis-
had comparable glycemic control [17, 30], but betterease in patients with newly diagnosed type 2 diabetes who
control than older diabetic individuals in the Wisconsintook part in a randomized controlled trial of treatment
Epidemiologic Study of Diabetic Retinopathy (WESDR)for diabetes. We show that a substantial proportion, ap-
proximately one quarter of patients by ten years, develop study [31, 32].
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Table 3. Prevalence of the different stages of nephropathy with increasing duration of diabetes
Elevated plasma
Microalbuminuria or worse Macroalbuminuria or worse creatinine or renal
nephropathy nephropathy replacement therapy
Time Number alive Observed Observed Observed
years and examined % (95% CI) (N ) Modeled % (95% CI) (N ) Modeled % (95% CI) (N )
0 5097 7.3% (6.6–8.0) (370) 7.3% 0.7% (0.5–1.0) (37) 0.7% 0% (0.0–0.0) (0)
5 4791 17.3% (16.3–18.4) (830) 16.2% 3.1% (2.6–3.6) (149) 2.8% 0.4% (0.2–0.6) (19)
10 2799 24.9% (23.3–26.5) (696) 23.5% 5.3% (4.5–6.1) (148) 5.1% 0.8% (0.5–1.1) (22)
15 435 28.0% (23.8–32.3) (122) 29.4% 7.1% (4.7–9.5) (31) 7.6% 2.3% (0.9–3.7) (10)
20 — — 34.3% — 10.0% —
25 — — 38.3% — 12.2% —
Table 4. Proportion of patients alive, based on life table estimates, similar to survival rates for diabetic patients under age
ten years following onset of different stages of nephropathy
65 years on dialysis in the UK (80.5%, 95% CI 76.2 to
Proportion of patients alive 84.4%) [3] or in the US [5].
From (95% CI) ten years later Our model predicts that patients without microalbu-
No nephropathy 87.1% (86.8–87.3) minuria at diagnosis of diabetes remain free of nephropa-
Microalbuminuria 70.8% (67.4–74.2)
thy for a median of approximately 19 years. This is aMacroalbuminuria 65.1% (57.5–72.6)
Elevated plasma creatinine or longer time period than previously estimated [37]. Of
renal replacement therapy 8.5% (0–100) patients who develop microalbuminuria, the median time
to macroalbuminuria or worse is estimated to be 11 years.
This implies that for individuals diagnosed with diabetes
The prevalence of nephropathy we report is also lower later in life, the chance of significant renal impairment
than other studies. In WESDR, fifteen years following is low; by contrast, for a person diagnosed earlier in life,
diagnosis of diabetes, 54.8% of individuals had no evi- the potential for renal failure increases. As the age at
dence of microalbuminuria or worse, compared to 72% diagnosis of type 2 diabetes falls [38], the burden of ad-
of patients in this study [33]. By contrast, less than 30% vanced renal disease will likely worsen, in part because
of Pima Indians are without microalbuminuria or worse younger patients with ESRD live longer than older pa-
after 15 to 19 years [13]. tients [39]. It has been suggested that “most patients
Since microalbuminuria is a risk factor for more ad- reach end-stage renal failure within 10 years after the
vanced nephropathy [34, 35], it follows that the rates we onset of proteinuria” [40]. This study suggests that half
report for macroalbuminuria or more advanced nephropa- of macroalbuminuric patients who reach elevated plasma
thy may be lower than some other populations, although creatinine or renal replacement therapy do so by 9.7
they are coherent with those observed among newly- years. The median survival based on small numbers for
diagnosed diabetic patients in Rochester, Minnesota at patients on renal replacement therapy from this study
1.5% per year, acknowledging that persistent proteinuria at 3.0 years was less than another modeled value (4.6
was defined as proteinuria in excess of 40 mg/dL [10]. years) [41], but similar to an observed value of 2.7 years
In Denmark, 3% developed overt nephropathy in six among diabetic dialysis patients in France [42].
years [7] and in Israel, 16% of patients in eight years Other models for diabetic renal disease exist [4, 41,
[9]; the UKPDS observed that 2.6% develop macroalbu- 43–45], but often depend on transition probabilities ob-
minuria or worse by six years and 3.8% by eight years served in type 1 diabetes, and have not modeled progres-
(cumulative incidence) among those free of macroalbu- sion from normal renal function at diagnosis of diabetes
minuria at diagnosis of diabetes. The annual incidence to renal failure and death, or have not used estimates
of renal failure among diabetic Oklahoma Indians was derived from a single cohort. Models can be used to project
1.0%, 1.9% and 5.6% in patients with no, slight, or heavy the national burden of renal disease [4], to assess the eco-
proteinuria at baseline, respectively [36]. In the UKPDS, nomics of preventive interventions [43, 45] or to estimate
the annual incidence of elevated plasma creatinine or a treatment benefit [41]. Other potential uses include esti-
renal replacement therapy was 0.1% for patients without mating event rates, for example, for clinical trials, or the
nephropathy, 0.3% for those with microalbuminuria or numbers of individuals who require treatment, such as
worse, and 2.3% for patients with macroalbuminuria. the number of microalbuminuric patients with type 2 dia-
The death rates for patients with elevated plasma cre- betes who might merit treatment with angiotensin convert-
atinine or renal replacement therapy in the UKPDS are ing enzyme (ACE) inhibitors or angiotensin 2 blockers
comparable to other populations. UKPDS patients had [46, 47].
Our study extends the evidence that renal dysfunctiona one-year survival of 79.5% (95% CI 66.6 to 92.4%),
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is associated with cardiovascular mortality [48–50]. From is evidence that urinary albumin is better viewed as a
continuous risk factor [50]. We chose not to includea cohort of patients with predominantly type 2 diabetes
assembled in 1973, Mogensen observed an increasing death doubling of plasma creatinine as an endpoint, since the
modest levels of plasma creatinine among UKPDS sub-rate with increasing albumin concentration, although in-
creases in cardiovascular mortality were not clearly dem- jects meant that doubling of the value for many patients
onstrated [34]. As in the Danish cohort, the UKPDS had would not correspond to severe renal impairment. There
elevated standardized mortality ratios observed from five is a possibility that a susceptible pool of individuals exists,
years of follow-up and beyond [51]. For comparison with perhaps due to genetic traits, who will develop nephropa-
the cardiovascular death rates reported here, the approx- thy, such that after a number of years of diabetes, those
imate rate of coronary death in the general UK popula- without nephropathy are unlikely ever to develop it [58].
tion aged 55 to 64 was 0.5% in 1987, the midpoint of the If true, then our model may overestimate the prevalence
UKPDS [52]. Increasing albumin excretion may lead to for long durations of diabetes.
increased cardiovascular disease directly, or may be a With respect to generalizability, the rates we report,
marker of an underlying abnormality such as enhanced by definition, will be lower when compared to popula-
platelet aggregability, penetration of endothelium by tions at higher risk for nephropathy, and because the
atherogenic lipoprotein particles, or autonomic neuropa- UKPDS excluded patients who had a recent myocardial
thy [49, 50]. Our study patients with elevated plasma infarction and uncontrolled hypertension, among other
creatinine had a two- to threefold increased rate of car- factors [25]. However, in these populations, individuals
diovascular disease relative to subjects with macroalbu- might die before developing proteinuria.
minuria only. In the HOPE study, patients with a plasma In conclusion, this study provides robust estimates of
creatinine 124 mol/L or microalbuminuria had a rate the rate of development of nephropathy in type 2 diabetes
of cardiovascular events double that of other patients in a large, predominantly white, medically treated, newly
[50 53]. Since individuals with macroalbuminuria are at diagnosed cohort. Microalbuminuria is relatively common,
greater risk of cardiovascular death than they are even estimated in this paper as one quarter of patients by ten
to require renal replacement therapy, these patients are years following diagnosis of diabetes, whereas macroalbu-
priority candidates for cardiovascular disease-reducing, minuria and renal replacement therapy are less so. The
as well as renoprotective, interventions. Although pa- burden of nephropathy will increase in the future as the
tients with significant renal disease are often excluded incidence of diabetes increases and the age of onset de-
from intervention trials [49], existing evidence in patients clines, although the effects may be lessened by the use
with renal insufficiency supports intervention [53–55]. of emerging therapies. As a means to estimate the magni-
The advantages of this study are its size, its prospective tude of nephropathy in type 2 diabetes, the results of this
design, the inclusion of both early and advanced states study are likely to aid and inform providers, planners,
of nephropathy within the same population, and enroll- insurers, economists, clinical trialists, and individuals with
ment of subjects at diagnosis of diabetes. Another advan- type 2 diabetes.
tage is the relatively lengthy follow-up, and the provision
of modeled values for even longer durations of diabetes. ACKNOWLEDGMENTS
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